[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-341087-105":59,"doc-detail-341087-en":122},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":115,"head_meta":117,"extra_data":119,"updated_unix":121},105,"en","co-delivery-of-cas9-mrna-and-guide-rnas-for-editing-of-lgmn-gene-represses-breast-cancer-cell-metastasis","Co-delivery of Cas9 mRNA and guide RNAs for editing of LGMN gene represses breast cancer cell metastasis","","Study investigates co-delivery of Cas9 mRNA and guide RNA (gRNA) using lipid nanoparticles (LNP) to edit the LGMN gene, targeting legumain, a lysosomal cysteine endopeptidase linked to cancer aggressiveness. gRNA templates were prepared for in-vitro transcription, Cas9 mRNA production was optimized, and lysosomal/autophagic function and metastatic behaviors were assessed in vitro and in vivo. Results show impaired lysosomal/autophagic degradation and reduced migration, invasion, and clone formation, with fewer lung metastases in mice, suggesting potential for breast tumor metastasis treatment.",{"@graph":69,"@context":114},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/co-delivery-of-cas9-mrna-and-guide-rnas-for-editing-of-lgmn-gene-represses-breast-cancer-cell-metastasis/341087/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/co-delivery-of-cas9-mrna-and-guide-rnas-for-editing-of-lgmn-gene-represses-breast-cancer-cell-metastasis/341087.png","ImageObject",300,407,{"name":92,"@type":93},"Ava Thompson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108],{"name":109,"@type":110,"acceptedAnswer":111},"Why is LGMN/legumain considered a therapeutic target for breast cancer metastasis?","Question",{"text":112,"@type":113},"Legumain is enriched in lysosomes of cancer cells and is associated with increased aggressiveness and migratory behavior across multiple cancers, including breast cancer. Because lysosome-centered signaling supports metastatic processes, editing LGMN via CRISPR/Cas9 is proposed as an anti-metastasis strategy.","Answer","https://schema.org",{"og:url":83,"og:type":116,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":118,"canonical":83},"index,follow",{"doc_id":120,"site_id":62},341087,1790119268,{"code":4,"msg":5,"data":123},{"doc_id":120,"user_id":124,"nickname":92,"user_avatar":125,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":126,"file_id":127,"file_url":128,"file_type":129,"file_size":130,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":131,"language":132,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":133,"faqs":134,"seo_title":135,"seo_description":67,"update_tm":136,"read_time":137,"preview_page_count":19,"preview_urls":138},1649267921044,"https://us-avatar.wpscdn.com/avatar/1800007509477c92dfb?_k=1786009248482753345","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nCo‑delivery of Cas9 mRNA and guide RNAs for editing of LGMN gene represses breast cancer cell metastasis  \nYue Wang1, Yatu Peng2, Guanghui Zi1, JinChen1 & Baowei Peng1*  \nLegumain (or asparagine endopeptidase/AEP) is a lysosomal cysteine endopeptidase associated with increased invasive and migratory behavior in a variety of cancers. In this study, co‑delivery of Cas9 mRNA and guide RNA (gRNA) by lipid nanoparticles (LNP) for editing of LGMN gene was performed. For in‑vitro transcription (IVT) of gRNA, two templates were designed: linearizedpUC57‑T7‑gRNA andT7‑gRNA oligos, and the effectiveness of gRNA was verified in multiple ways. Cas9 plasmid was modified and optimized for IVT of Cas9 mRNA. The effects of LGMN gene editing on lysosomal/autophagic function and cancer cell metastasis were investigated. Co‑delivery of Cas9 mRNA and gRNA resulted in impaired lysosomal/autophagic degradation, clone formation, migration, and invasion capacity of cancer cells in‑vitro. Experimental lung metastasis experiment indicates co‑delivery of Cas9 mRNA and gRNA by LNP reduced the migration and invasion capacity of cancer cells in‑vivo. These results indicate that co‑delivery of Cas9 mRNA and gRNA can enhance the efficiency of CRISPR/Cas9‑mediated gene editing in‑vitro and in‑vivo, and suggest that Cas9 mRNA and gRNA gene editing of LGMN may be a potential treatment for breast tumor metastasis.  \nLegumain was originally discovered in common legumes 1,2. In 1996, it was first identified as a specific protease encoded by the LGMN gene on chromosome 14 in humans3. Legumain selectively cleaves substrates after asparagine (N) residues4, thus earning the name asparagine endopeptidase (AEP)1. AEP has multiple functions, including in maturation of other proteases such as MMPs and in immune regulation5,6. It has also been shown to participate in the regulation of vascular homeostasis, which plays a significant role in both cardiovascular and cerebrovascular diseases7. Recently, researchers have found that legumain is present in a variety of solid tumors, such as breast cancer8,9 and melanoma 10. In addition, it is also associated with increased aggressiveness and migratory behavior in cancers, including breast, prostate, colorectal, and gastric cancers11–13. Not surprisingly, legumain has been associated with poor prognosis in several types of malignant tumors11, 14.  \nThe CRISPR-Cas system is an innate immune system in prokaryotes that degrades invading foreign DNA15. In recent years, the CRISPR-Cas9 genome editing technology has emerged as a potentially powerful tool for treating human diseases16, 17. As a tool of gene therapy, it can treat various diseases through DNA editing technology18. For many solid tumors, such as breast cancer, the metastasis and spread of tumor cells are important causes of death in cancer patients and also major challenges in cancer treatment19. The use of CRISPR-Cas9 gene editing technology to knock out pathogenic or related target genes in the genome to treat cancer is of great significance for tumor gene therapy20,21. Recent studies have found that AEP is up-regulated in lysosomes in cancer cell22. Since lysosomes act as cellular centers for signaling such as Akt activation23–25, which makes AEP an attractive therapeutic target for the treatment of tumor metastasis. Knocking out AEP through CRISPR-Cas9 gene editing technology to inhibit tumor metastasis may be a feasible, effective anti-tumor strategy.  \nWhen considering gene-editing strategies as a therapeutic approach for cancer treatment, it’s critical to anticipate and understand potential resistance mechanisms that cancer cells might develop. This is important for improving the effectiveness of the treatment and for the development of strategies to overcome resistance26,27. Some potential resistance mechanisms include the following: (1) Cancer cells could develop mutation in the target ","cbCais7WpxUaeC7Q","https://ap.wps.com/l/cbCais7WpxUaeC7Q","pdf",7333149,13,"English","# Overview\n## Background on legumain and LGMN\n## CRISPR-Cas9 rationale for cancer therapy\n# Experimental approach\n## gRNA template design and validation\n## Cas9 plasmid modification and IVT optimization\n## LNP co-delivery and functional assays\n# Results\n## Effects on lysosomal/autophagic degradation\n## Effects on clone formation, migration, invasion\n## In-vivo lung metastasis outcomes\n# Implications and resistance considerations\n## Potential resistance mechanisms in gene editing","[{\"question\":\"Why is LGMN/legumain considered a therapeutic target for breast cancer metastasis?\",\"answer\":\"Legumain is enriched in lysosomes of cancer cells and is associated with increased aggressiveness and migratory behavior across multiple cancers, including breast cancer. Because lysosome-centered signaling supports metastatic processes, editing LGMN via CRISPR/Cas9 is proposed as an anti-metastasis strategy.\"}]","Co-delivery of Cas9 mRNA and guide RNAs for editing of LGMN gene represses breast cancer cell metastasis | PDF",1790040255,33,[139,143,147,151],{"page_no":8,"url":140,"width":141,"height":142},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b7fcaa6975bbc2533107c1d0d9ac7030.webp",983,1291,{"page_no":14,"url":144,"width":145,"height":146},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d37935d5179869ef63680d2262370a54.webp",982,1290,{"page_no":81,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ffefa6e35e51d9131234f459b37d13da.webp",981,1289,{"page_no":19,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/488292981460bb3a6f35ea2ecc9b78ca.webp",980,1287]